| A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. | |
| | |
MedLine Citation:
|
PMID: 3311440 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A total of 100 male Zambian patients with symptomatic falciparum malaria were treated with either two tablets of mefloquine plus sulfadoxine-pyrimethamine (Fansimef) or three tablets of sulfadoxine-pyrimethamine (Fansidar) as a single dose. The patients were kept under observation from day 0 (day of treatment) to day 28 and all were cured. An S-type of response was seen in all patients; one patient in the Fansimef group inexplicably remained positive for Plasmodium falciparum trophozoites until day 6. There were no cases of recrudescence.The rate of clearance of parasitaemia was similar in both groups. The rate of clearance of fever was marginally faster in the Fansimef group. Side-effects such as pruritus, diarrhoea and abdominal pain occurred after both drugs but were mild and transient; tolerance was slightly better with Fansimef. Severe orthostatic hypotension occurred in 20% of the Fansidar patients and in only 2% of the Fansimef patients; this was reversed by bed rest. Haematological and biochemical parameters were generally not modified in an undesirable manner by the administration of these drugs. |
| | |
Authors:
|
J M Ekue; D E Phiri; U K Sheth; M Mukunyandela |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Bulletin of the World Health Organization Volume: 65 ISSN: 0042-9686 ISO Abbreviation: Bull. World Health Organ. Publication Date: 1987 |
Date Detail:
|
Created Date: 1987-12-02 Completed Date: 1987-12-02 Revised Date: 2010-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 7507052 Medline TA: Bull World Health Organ Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 369-73 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Animals Antimalarials / administration & dosage, therapeutic use* Child Double-Blind Method Drug Combinations / administration & dosage, therapeutic use Humans Malaria / drug therapy* Male Mefloquine* / analogs & derivatives* Middle Aged Plasmodium falciparum Pyrimethamine / administration & dosage, therapeutic use* Quinolines / administration & dosage, therapeutic use* Random Allocation Sulfadoxine / administration & dosage, therapeutic use* Sulfanilamides / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antimalarials; 0/Drug Combinations; 0/Quinolines; 0/Sulfanilamides; 2447-57-6/Sulfadoxine; 37338-39-9/sulfadoxine-pyrimethamine; 53230-10-7/Mefloquine; 58-14-0/Pyrimethamine; 69191-18-0/mefloquine-sulfadoxine-pyrimethamine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a dou...
Next Document: The efficiency of sporozoite transmission in the human malarias, Plasmodium falciparum and P. vivax.